-

BostonGene Named One of Massachusetts Best Genetics and Bioinformatics Startups

 Criteria for Recognition Includes Exceptional Performance in Innovation, Growth, Management or Societal Impact

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, announced today that BestStartup.us had named BostonGene a top Massachusetts startup in two categories, “Genetics” and “Bioinformatics."

BestStartup.us evaluated companies on various criteria, including innovation, growth, management, or societal impact. BestStartup.us aims to highlight companies promoting innovative products and breakthrough ideas across the United States.

BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to advance the standard of care, accelerate research, and improve economics. The BostonGene Tumor Portrait Test™, based on integrated genomic and transcriptomic analysis, propels precision medicine into daily clinical practice and supports physicians in actualizing personalized therapy for cancer patients. BostonGene collaborates with many of the leading cancer centers across the United States for research and clinical adoption.

“We are honored to receive this recognition from BestStartup.us,” said Erin O’Reilly, Senior Director, Marketing at BostonGene. “The acknowledgment validates our ongoing commitment to identify novel and personalized treatment options through next-generation multi-platform analytics, further advancing and optimizing outcomes for each cancer patient.”

About BostonGene Corporation

BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics. BostonGene Tumor PortraitTM Tests reveal key drivers of each tumor, including immune microenvironment properties, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene Tumor PortraitTM Tests generate a personalized roadmap for therapeutic decision-making for each cancer patient. For more information, visit BostonGene at http://www.BostonGene.com.

Contacts

Media:

BostonGene
Erin O’Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com

BostonGene Corporation


Release Versions

Contacts

Media:

BostonGene
Erin O’Reilly
+1-781-366-7049
Erin.Oreilly@BostonGene.com

More News From BostonGene Corporation

BostonGene to Present Multimodal AI Advances in Tumor-of-Origin Classification and Tumor Microenvironment Profiling at the ESMO AI & Digital Oncology Congress 2026

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of an AI model for tumor and immune biology, today announced its participation in ESMO AI & Digital Oncology Congress 2026 taking place November 16–18, 2026 in Berlin, Germany. The international forum unites oncologists, data scientists, and industry leaders to showcase advances in AI and computational biology across cancer care. BostonGene will demonstrate how its multimodal AI platform addresses critical oncology challenges, including...

BostonGene Showcases Biologically Grounded AI at ACR Convergence 2026 to Advance Precision Rheumatology and Autoimmune Disease Stratification

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of an AI model for tumor and immune biology, announced today that it will present new data demonstrating the application of its biologically grounded AI in non-oncology indications at the American College of Rheumatology (ACR) Convergence 2026. ACR Convergence 2026, the world's premier rheumatology event, will be held November 6–11 at the Orange County Convention Center in Orlando, Florida. BostonGene combines multimodal profiling with biol...

BostonGene Wins Three Gold Stevie® Awards

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of an AI model for tumor and immune biology, today announced that it has been awarded three Gold Stevie® Awards in the 2026 Stevie® Awards for Technology Excellence, taking top honors as Company of the Year, New Product of the Year, and Technology Breakthrough of the Year in Biotechnology. The awards recognize a fundamental shift in how oncology drugs are developed. Traditional AI approaches in drug development often rely on retrospective a...
Back to Newsroom